Technology
Our lead immunotherapy CT101 (anti-cancer drug) exhibits novel and potent pharmacological properties:
Induces robust immune effector cell activation and migration to the tumor microenvironment (TME).
Has potent anti-metastatic properties by preventing the Epithelial-to-Mesenchymal Transition (EMT) on cancer cells.
Reduces the expression of 4 negative immune checkpoints on immune cells
Blocks and antagonizes tumor-derived immunosuppressive factors.
Prevents Treg accumulation in tumor sites.
Disrupts tumor-induced angiogenesis (blood vessel formation).
Promotes adaptive immunity that prevents cancer relapses.
